AMGENAMGENAMGEN

AMGEN

No trades
See on Supercharts
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪151.16 B‬EUR
7.10EUR
‪6.09 B‬EUR
‪25.38 B‬EUR
‪536.14 M‬
Beta (1Y)
0.64
Employees (FY)
‪26.7 K‬
Change (1Y)
‪+1.5 K‬ +5.95%
Revenue / Employee (1Y)
‪1.05 M‬EUR
Net income / Employee (1Y)
‪251.57 K‬EUR

About Amgen Inc.


CEO
Robert A. Bradway
Website
Headquarters
Thousand Oaks
Founded
1980
FIGI
BBG000QFTC54
Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. It operates through Human Therapeutics segment. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬

See all ideas 

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
AMGN5186584
Amgen Inc. 2.77% 01-SEP-2053
Yield to maturity
6.88%
Maturity date
Sep 1, 2053
AMGN5235280
Amgen Inc. 3.0% 15-JAN-2052
Yield to maturity
6.47%
Maturity date
Jan 15, 2052
US31162CS7
AMGEN 20/50
Yield to maturity
6.44%
Maturity date
Feb 21, 2050
AMGN5235282
Amgen Inc. 2.8% 15-AUG-2041
Yield to maturity
6.37%
Maturity date
Aug 15, 2041
US31162DG2
AMGEN 22/62
Yield to maturity
6.33%
Maturity date
Feb 22, 2062
US31162CR9
AMGEN 20/40
Yield to maturity
6.33%
Maturity date
Feb 21, 2040
US31162BP4
AMGEN 12/43
Yield to maturity
6.25%
Maturity date
May 15, 2043
AMGD
AMGEN 22/52
Yield to maturity
6.25%
Maturity date
Feb 22, 2052
US31162BZ2
AMGEN 15/45
Yield to maturity
6.15%
Maturity date
May 1, 2045
AMGN4437315
Amgen Inc. 4.563% 15-JUN-2048
Yield to maturity
6.08%
Maturity date
Jun 15, 2048
US31162DK3
AMGEN 22/53
Yield to maturity
6.08%
Maturity date
Mar 1, 2053

Explore more bonds 

Frequently Asked Questions


The current price of 4AMGN is 281.45 EUR — it has increased by 2.27% in the past 24 hours. Watch AMGEN stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on EUROTLX exchange AMGEN stocks are traded under the ticker 4AMGN.
4AMGN stock has risen by 0.79% compared to the previous week, the month change is a −3.60% fall, over the last year AMGEN has showed a 16.01% increase.
We've gathered analysts' opinions on AMGEN future price: according to them, 4AMGN price has a max estimate of 383.47 EUR and a min estimate of 189.37 EUR. Watch 4AMGN chart and read a more detailed AMGEN stock forecast: see what analysts think of AMGEN and suggest that you do with its stocks.
4AMGN reached its all-time high on Jul 25, 2024 with the price of 311.95 EUR, and its all-time low was 79.20 EUR and was reached on Oct 9, 2013. View more price dynamics on 4AMGN chart.
See other stocks reaching their highest and lowest prices.
4AMGN stock is 2.22% volatile and has beta coefficient of 0.64. Track AMGEN stock price on the chart and check out the list of the most volatile stocks — is AMGEN there?
Today AMGEN has the market capitalization of ‪151.16 B‬, it has increased by 2.86% over the last week.
Yes, you can track AMGEN financials in yearly and quarterly reports right on TradingView.
AMGEN is going to release the next earnings report on Feb 4, 2025. Keep track of upcoming events with our Earnings Calendar.
4AMGN earnings for the last quarter are 5.01 EUR per share, whereas the estimation was 4.74 EUR resulting in a 5.79% surprise. The estimated earnings for the next quarter are 4.81 EUR per share. See more details about AMGEN earnings.
AMGEN revenue for the last quarter amounts to ‪7.64 B‬ EUR, despite the estimated figure of ‪7.63 B‬ EUR. In the next quarter, revenue is expected to reach ‪8.45 B‬ EUR.
4AMGN net income for the last quarter is ‪2.54 B‬ EUR, while the quarter before that showed ‪696.47 M‬ EUR of net income which accounts for 264.95% change. Track more AMGEN financial stats to get the full picture.
Yes, 4AMGN dividends are paid quarterly. The last dividend per share was 2.12 EUR. As of today, Dividend Yield (TTM)% is 3.01%. Tracking AMGEN dividends might help you take more informed decisions.
AMGEN dividend yield was 2.96% in 2023, and payout ratio reached 68.24%. The year before the numbers were 2.95% and 64.07% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Nov 24, 2024, the company has ‪26.70 K‬ employees. See our rating of the largest employees — is AMGEN on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. AMGEN EBITDA is ‪10.85 B‬ EUR, and current EBITDA margin is 44.11%. See more stats in AMGEN financial statements.
Like other stocks, 4AMGN shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade AMGEN stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So AMGEN technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating AMGEN stock shows the buy signal. See more of AMGEN technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.